Treatment of Concurrent Minimal Change Disease and Epstein Barr Virus–Driven Post-transplant Lymphoproliferative Disorder With Rituximab Following Hematopoietic Stem Cell TransplantationLouise Ainley, Ruth J. Pepper, Steven Law et al.|Kidney International Reports|2020Cited by 3